"We should be thinking about preparedness...if this happens again, what might our role be, how might we best care for patients" Brilliant keynote from fellow @Cambridge_Uni alumna @DoctorYasmin #ACR21! Inspiring to hear about her journey through medicine (and beyond)! @RheumNow https://t.co/AyoP1S3zmL

Wonderful keynote lecture by @DoctorYasmin on The Covidization of Rheumatology: What Will or Won’t Change Beyond the COVID-19 Pandemic #ACR21 @RheumNow

Full circle for VEXAS, from breaking at last years ACR to making the year in review for #ACR21 @RheumNow https://t.co/1iGNPvyzQi

🙋I cannot be alone in saying I do not #ACR21 @RheumNow https://t.co/AxKK03TJHY

A quick recap slide on VEXAS syndrome presentation. #ACR21 @RheumNow @petercgrayson https://t.co/4x8hBEFWg2

Still like one of those people like me who struggles with the acronym #VEXAS? Here we go! 1⃣Vacuoles, 2⃣E1 enzyme, 3⃣X-linked, 4⃣autoinflammatory, 5⃣somatic Year in review at #ACR21 @RheumNow https://t.co/gMgFPF6NcS

• https://www.nejm.org/doi/full/10.1056/NEJMoa2026834

"How can we institute cultural change?" -@DoctorYasmin asks everyone to weigh in. @DrDavidKarp @ACRhem #ACR21 @rheumnow @PeterHotez @AWIRGROUP #MedTwitter #RheumTwitter [Quote tweet your answer here]

Michael Brenner, Basic Science Year in review: Auto-antibodies against interferon, present prior to COVID-19, mostly in men and increases with age: increases risk to #COVID19 mortality #ACR21 @RheumNow https://t.co/5sFqcBtStD

Who would have thought red cells would be so important in SLE? #ACR21 @RheumNow https://t.co/qnPuZUmEjh

NETosing is now a verb! Dr. Brenner: #BasicScience #YearinReview #ACR21 IFN sig driven by: 👉nucleic acid from PMNs NETosing 👉IC's containing Ab and nucleic acid 👉pDC's recog nucleic acids, produce type I IFN risk alleles 👉Erythroid mitochondrial retention👈 @RheumNow https://t.co/dsNRj7oSBK

OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27

#ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their mitochondria (Mito+ RBCs) and their frequency correlated with disease activity and blood⬆️IFN @RheumNow https://t.co/ZixgAbOWJ0 https://t.co/hkTWE4m7Ph

• DEFINE_ME

ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8

#ACR21 #YearinReview Avacopan: The game changer for ANCA #vasculitis?🧐 🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001) 🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001) @RheumNow https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu

• https://bit.ly/2ZNHhAi

👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21 Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n